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Risk-reducing hysterectomy and bilateral salpingo-
oophorectomy in female heterozygotes of pathogenic
mismatch repair variants: a Prospective Lynch Syndrome
Database report
Mev Dominguez-Valentin, PhD , Emma J. Crosbie, PhD, MRCOG et al.#
PURPOSE: To determine impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) on gynecological cancer
incidence and death in heterozygotes of pathogenic MMR (path_MMR) variants.
METHODS: The Prospective Lynch Syndrome Database was used to investigate the effects of gynecological risk-reducing surgery
(RRS) at different ages.
RESULTS: Risk-reducing hysterectomy at 25 years of age prevents endometrial cancer before 50 years in 15%, 18%, 13%, and 0% of
path_MLH1, path_MSH2, path_MSH6, and path_PMS2 heterozygotes and death in 2%, 2%, 1%, and 0%, respectively. Risk-reducing
BSO at 25 years of age prevents ovarian cancer before 50 years in 6%, 11%, 2%, and 0% and death in 1%, 2%, 0%, and 0%,
respectively. Risk-reducing hysterectomy at 40 years prevents endometrial cancer by 50 years in 13%, 16%, 11%, and 0% and death
in 1%, 2%, 1%, and 0%, respectively. BSO at 40 years prevents ovarian cancer before 50 years in 4%, 8%, 0%, and 0%, and death in
1%, 1%, 0%, and 0%, respectively.
CONCLUSION: Little benefit is gained by performing RRS before 40 years of age and premenopausal BSO in path_MSH6 and
path_PMS2 heterozygotes has no measurable benefit for mortality. These findings may aid decision making for women with LS who
are considering RRS.
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INTRODUCTION
Lynch syndrome (LS) is a common hereditary cancer predisposi-
tion syndrome, present in an estimated 1 in 300 individuals, based
on prevalence of the underlying genetic abnormalities in the
general population. LS is caused by pathogenic variants in one of
four DNA mismatch repair (MMR) genes (path_MMR): path_MLH1,
path_MSH2, path_MSH6, and path_PMS2, each of which result in
different risks for cancers, including colorectal, endometrial,
ovarian, stomach, small bowel, bile duct, pancreas, urinary tract,
brain, and prostate cancer.1–5 In women with LS, gynecological
cancers are as common as gastrointestinal cancers. Until recently,
clinical guidelines were similar for heterozygotes of all path_MMR
genetic variants, endometrial cancer prognosis was assumed to be
similar in heterozygotes and MMR variant-negative individuals,
and the prognosis for ovarian cancer was assumed to be similar to
ovarian cancer in path_BRCA1 heterozygotes. The recent Manche-
ster International Consensus Group publication6 described the risk
for, and survival after, gynecological cancers in LS by genotype, as
initially reported by the Prospective Lynch Syndrome Database
(PLSD).1–4,7 Later, the PLSD reported findings in an additional
independent cohort of path_MMR heterozygotes that validated
the results from its original cohort and allowed merger of both
cohorts to obtain more precise risk estimates and calculation of 5-
year and 10-year crude survival after cancer.2
Risk-reducing surgery (RRS) including total hysterectomy and
bilateral salpingo-oophorectomy (BSO) prevents gynecological
cancer in Lynch syndrome.8 The Manchester International
Consensus Group strongly recommended that risk-reducing
hysterectomy and BSO are offered no earlier than 35–40 years
of age, following completion of childbearing in path_MLH1,
path_MSH2, and path_MSH6 heterozygotes but the data support-
ing such recommendations are not strong, and various practices
currently exist. There was insufficient evidence to strongly
recommend risk-reducing surgery for path_PMS2 heterozygotes.6
In this report, we determine the impact on cancer incidence and
mortality of RRS at different ages in heterozygotes of pathogenic
MMR variants.
MATERIALS AND METHODS
The PLSD is an international, multicenter, prospective observational study
without a control group. The PLSD design and its inclusion criteria have
been described previously in detail.1,3,4,9,10
In brief, path_MMR heterozygotes, including probands and their
relatives, were recruited for prospective follow-up in each participating
center. Genetic variants were assumed to be inherited and were found by
genetic testing either prior to, at, or after inclusion for follow-up. Inclusion
was from the first prospectively planned and completed colonoscopy, and
all recruits had subsequent follow-up of one year or more. Any cancers that
were diagnosed before or at the same age as the first prospectively
planned and completed colonoscopy were scored as previous cancers.
Time to first cancer after inclusion was calculated for each organ or groups
of organs. Only heterozygotes with pathogenic variants confirmed as class
4 or 5 (clinically actionable) in the International Society for Gastrointestinal
Hereditary Tumors (InSiGHT) database (https://databases.lovd.nl/shared/
genes) were included. Each patient was censored at the age at which the
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last information was available, which might have been a colonoscopy, any
other clinical examination, a report from an examination done by others, or
information that the patient had died, whichever came last. Observation
time was censored at organ removal (therapeutic or prophylactic) when
calculating incidences for cancer in specific organs.1
Impact on cancer incidence of risk-reducing hysterectomy and/or
BSO by age and gene
The inclusion criteria for calculating the endometrial and ovarian cancer
risks were (1) female, (2) heterozygotes with pathogenic (class 4 or 5) MMR
variant as classified in the InSiGHT database (http://insight-database.org/),
(3) no previous hysterectomy or BSO, and (4) aged 25 to 74 years at start of
follow-up. The following information was used for analyses: age at last
observation, incident endometrial and/or ovarian cancer, path_MMR
variant, age at hysterectomy, and age at oophorectomy. In this report,
we assume the oophorectomies undertaken were all BSO.
Endometrial and ovarian cancer risks are reported by 5-year age groups.
These risks may be considered to represent cancers that would have been
prevented if surgery had been undertaken before the ages concerned.
All risks used for calculations and their 95% confidence intervals are
derived from our previous publications.1–4 Briefly, annual incidence rates
(AIRs) by age were calculated in 5-year cohorts from 25 to 75 years of age.
Cumulative incidence, denoted by Q, was computed starting at age 25,
assuming zero incidence rate before age 25, using the formula Q(age)=Q
(age− 1)+ [1−Q(age− 1)] × AIR(age) where AIR(age) is the annual
incidence rate as estimated from the corresponding 5-year interval. The
observed AIRs and cumulative incidence of endometrial and/or ovarian
cancer in the current data set have not been described previously and are
now presented here in the Supplementary file.
Risk of dying from endometrial or ovarian cancer
As in all previous PLSD reports, cancer incidence at 25 years of age (the
minimum age from which PLSD collects prospective data) was assumed to
be zero. In this report, we provide estimates of the risk of dying following
endometrial or ovarian cancer, stratified by MMR gene from 25 to 69 years
of age. As displayed at our interactive website (www.plsd.eu), the
confidence intervals for these measures are wide for patients with
heterozygous path_MSH6 and path_PMS2 variants, and the point estimates
of risks for patients with these genotypes must be used with caution.
Survival after cancer was estimated by the Kaplan–Meier survival
function as crude survival from age at diagnosis until last observation or
death. All the AIRs and cumulative incidences are prospectively observed
empirical observations, while the survival following endometrial and/or
ovarian cancer was calculated as follows: at any given age for cumulative
incidences in the tables for endometrial or ovarian cancer separately, we
calculated the relative risk for having endometrial or ovarian cancer as the
incidence of the one divided by the sum of the two incidences.
Survival after endometrial and/or ovarian cancer was calculated as
follows. The following observed factors (with acronyms) were entered into
the calculations: risk of endometrial cancer (ECrisk), risk of ovarian cancer
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(OCrisk), risk of ovarian and/or endometrial cancer (ECOCrisk), survival after
endometrial cancer (ECsurvival), and survival after ovarian cancer (OCsurvival).
The three former were age-dependent while the two latter were the same
for all ages. From the two latter, the difference between the survival for
ovarian and endometrial cancer (SURVdiff) was (ECsurvival – OCsurvival)= 5%,
which was the same for all ages. For each age cohort given in the table, the
fraction of endometrial cancer (ECfraction) was calculated as the risk for
endometrial cancer divided by the sum of the risks for endometrial and
ovarian cancer as ECrisk/(ECrisk+OCrisk). OC survival was lower than EC
survival and the survival when ovarian and/or endometrial cancer was
scored as an event; the interpolated combined survival indicated in the
table was calculated as OCsurvival+ SURVdiff *ECfraction for all age groups.
RESULTS
Survival after endometrial or ovarian cancer
There were 58, 61, 18, and 4 cases of prospectively observed
endometrial cancer included in the survival analyses in
path_MLH1, path_MSH2, path_MSH6, and path_PMS2 heterozy-
gotes, respectively. There were 22, 23, 1, and 1 prospectively
detected ovarian cancer cases included in the survival analyses
in path_MLH1, path_MSH2, path_MSH6, and path_PMS2 hetero-
zygotes, respectively. The average for all cases was used to
estimate survival for all heterozygotes in this report, but numbers
of path_MSH6 and path_PMS2 heterozygotes were too low for us
to determine whether the average survival pertains to these
heterozygotes. The numbers of cases were also too few to permit
calculations of survival by the age at which cancer occurred.
Estimates of five- and ten-year survival after endometrial or
ovarian cancer in LS, but not stratified by gene, have been
published previously.1 Figure 1 presents survival by gene. As
illustrated, there were no significant differences between the
genes. After a few early deaths, the curves for both endometrial
and ovarian cancer survival flatten out. This is in contrast to the
lower reported survival in path_BRCA1/2-associated or sporadic
ovarian cancer cases for which the survival curve does not flatten
out, although deaths beyond 5 years in BRCA1/2 cases are usually
predicted by recurrence before that time.11
Impact on cancer incidence and mortality of risk-reducing
hysterectomy and/or BSO by age and gene
Among the heterozygotes included in the last PLSD report1 there
were 7838 observed female years for path_MLH1 heterozygotes,
5487 for path_MSH2, 1614 for path_MSH6, and 862 for path_PMS2
that met the selection criteria for the current study.
In Table 1 and Fig. 2, the risks for endometrial cancer from 25 up
to 40, 50, 60, or 70 years of age are given by gene for patients who
did not have surgery before each respective age cutoff. Risks from
40, 50, and 60 up to 70 years of age are given to indicate the
potential for endometrial cancers to be prevented if hysterectomy
is undertaken at these ages. The risks for developing cancer in
each 10-year cohort are also given. In Table 2, the corresponding
risks for ovarian cancer by age and gene are given. The combined
risks for developing and dying from gynecological cancers by age
and gene in the absence of risk-reducing hysterectomy and/or
BSO are described in Table 3.
If risk-reducing hysterectomy were performed at 25 years of
age, endometrial cancer before 50 years would be prevented in
15%, 18%, 13%, and 0%, in patients with heterozygous
path_MLH1, path_MSH2, path_MSH6, and path_PMS2 variants,
respectively, and death in 2%, 2%, 1%, and 0%. If risk-reducing
BSO had been performed at 25 years of age, this would have
prevented the observed risks of ovarian cancer to age 50 years of
6%, 11%, 2%, and 0% in patients with heterozygous path_MLH1,
path_MSH2, path_MSH6, and path_PMS2 variants, respectively.
Correspondingly, the observed ovarian cancer death risks by age
50 years of 1%, 2%, 0%, and 0% would have been prevented
(Tables 1 and 2).T
ab
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Risk-reducing hysterectomy at 40 years of age was estimated to
prevent endometrial cancer by 50 years in 13%, 16%, 11%, and 0%
of patients and death in 1%, 2%, 1%, and 0% for path_MLH1,
path_MSH2, path_MSH6, and path_PMS2 heterozygotes, respec-
tively. Similarly, BSO carried out at 40 years of age was estimated
to prevent ovarian cancer before 50 years of age in 4%, 8%, 0%,
and 0%, and to prevent death before 50 years in 1%, 1%, 0%, and
0%, respectively.
DISCUSSION
In this report, we describe the consequences of RRS by age and
gene on incident gynecological cancer risk and associated deaths
using observational data from the PLSD from 25 to 69 years of age
for different intervention and observation endpoints. Our inten-
tion is to empower individual path_MMR heterozygotes to make
an informed choice regarding whether or not to have risk-
reducing gynecological surgery, and the optimal timing for this.
The results in Tables 1, 2, and 3 showing the consequences of
having or not having hysterectomy and/or BSO at various ages
demonstrate for path_MLH1, path_MSH2, and path_MSH6 hetero-
zygotes a small cumulative cancer risk (2%) up to 40 years of age,
and a more substantial risk (1.1% to 2.5% annual incidence)1 for
endometrial cancer from 40 years of age onward. For these
patients, the cumulative risk for ovarian cancer from 25 to 50 years
is 6%, 11%, and 2% respectively, which combined with the
average mortality, which is substantially lower than in BRCA1/2-
associated or sporadic ovarian cancer, indicate a risk of dying from
a premenopausal ovarian cancer to be 1%, 2%, and 0%,
respectively. There is also a risk for postmenopausal ovarian
cancer. Interpretation of estimates for RSS-associated endometrial
and ovarian cancer survival benefit indicates that the absolute
reduction in risk of cancer death achieved by very early RRS is
small. Performing RRS on 25-year-olds instead of 40-year-olds
yields incidence benefits of 0–3%, depending on the path_MMR
gene, for endometrial and ovarian cancer mortality. These risk
estimates are the best we currently have for informing the
outcome of premenopausal BSO.
For path_PMS2 heterozygotes, there is no demonstrable risk for
premenopausal endometrial or ovarian cancer, and therefore no
argument for considering premenopausal RRS. Similarly, no
increase in risk for postmenopausal ovarian cancer has been
demonstrated in path_PMS2 heterozygotes and therefore there is
no argument to consider postmenopausal BSO in this group
differently from the general population.1,12
The cumulative risks for endometrial cancer in path_MLH1,
path_MSH2, and path_MSH6 heterozygotes illustrated in Fig. 1
may give the impression that the annual incidence rates are
substantially lower at older ages. As seen in Table 1, however, this
is not so: the risk for endometrial cancer remains high at older
ages. Figure 1 shows the typical S-shaped curves generated by
conditional probabilities when risk initially increases with age.
Because there are fewer older female heterozygotes who have not
had endometrial cancer (or hysterectomy), residual risk at older
ages results in a lower number of cancer cases than at younger
ages, despite high annual incidence among older heterozygotes
who have not already had cancer. The higher the risk in younger
heterozygotes, the more pronounced this effect will be. Similarly,
the combined cumulative incidence by age for endometrial or
ovarian cancer as seen in Table 3 is slightly lower than the sum of
the two as presented in Tables 1 and 2, because standard
treatment of the one removes the risk of having the other at a
later time.
While Tables 1 and 2 indicate risks for cancer and survival by
age and gene at entry into each age group, any patient may input
her actual age and specific genetic variant into the interactive
website www.plsd.eu, which will return the risk for cancer in any
organ from her current age to any future selected age. From this,
one may calculate the risk of dying from that cancer using our
previously published survival estimates for LS patients who are
affected by that cancer. The figures derived are point estimates
and should be interpreted with appropriate caution.
Daily intake of acetyl-salicylic acid (aspirin) has been demon-
strated to reduce colon cancer risk in heterozygotes for path_MMR
variants by about 50%.12 A recent study also demonstrates a
reduction in endometrial cancer incidence in heterozygotes for
path_MMR variants taking acetyl-salicylic acid.13 The results in
both of these reports were not stratified by MMR gene or age. The
reduced cancer risk was a long-term effect and did not achieve
statistical significance for endometrial cancer alone.
This report calculates the impact of RRS on gynecological cancer
risk in path_MMR heterozygotes according to age and affected MMR
gene, and reports an estimate of a survival benefit in terms of deaths
that are actually prevented by RRS. Our calculations are based on
the largest international LS database in the world, reporting 15,800
prospective observation years for female path_MMR heterozygotes.
The prospective registration of incident cancers and associated
deaths minimizes ascertainment bias.
There are some limitations to the current study. Low number
of patients with path_MSH6 and path_PMS2 variants may reflect
that they are infrequently identified by the Amsterdam or
Bethesda criteria and are infrequently subjected to genetic
testing.14 With the advent of universal screening of colorectal
and endometrial cancers for LS, this situation is likely to
change.6 We restricted our analysis to report the prospectively
observed endometrial and ovarian cancer incidence and survival
in women who had not had prophylactic RRS to provide a robust
analysis of cancer risk and associated deaths using observational
data from the PLSD. We have not investigated for endometrial or
ovarian cancer after RRS. When considering survival, it must be
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remembered that the results presented here were obtained
prior to use of immunotherapy for microsatellite unstable
tumors: future treatment modalities may further improve the
survival, which is already much better than in sporadic or BRCA-
associated ovarian cancer. Improved imaging and liquid biopsy
may make early diagnosis and treatment more effective in
future. We have assumed that all bilateral oophorectomies were
BSO because type of RRS was not included in our data call.
There is a time-trend bias in the uptake of risk-reducing
hysterectomy and BSO: older women may not have had the
same option of early risk-reducing surgery that is advocated and
available today (and they may not have known they were at risk
when they were younger) and the uptake among older women
may not be representative of what younger heterozygotes
choose today. Because of the inherent time-trend bias,
from which no statistical procedures can escape, we considered
it inappropriate to investigate the reported uptake of these
interventions using more sophisticated statistical methods.
The offer of RRS is currently recommended for women with
path_MMR variants no earlier than 35–40 years of age6 (also see
Seppala et al.,7 patient 2286). Our intention is to empower
individual path_MMR heterozygotes to make an informed
choice. We do not make management recommendations; rather,
we promote personal choice for each path_MMR heterozygote
based on current data. Since the figures derived are point
estimates and should be interpreted with appropriate caution,
the use of this information in decision making should be
discussed with appropriately trained health-care professionals.
Conclusions
Our findings may be useful when disclosing results of genetic
testing for path_MMR variants, since female heterozygotes have to
decide which health-care options to select to manage their
gynecological cancer risks. Clinical guideline recommendations
should now be updated to take account of empirically observed
risks for endometrial or ovarian cancers in path_MMR hetero-
zygotes by age and gene.
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